BDTX Q3 2024 Earnings — Black Diamond Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

BDTXBlack Diamond Therapeutics, Inc.

$126M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$18M

Net Income

-$16M

EPS (Diluted)

$-0.28

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$11M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$138M

Total Liabilities

$40M

Stockholders' Equity

$97M

Cash & Equivalents

$23M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$18M	-$24M	+24.5%
Net Income	-$16M	-$23M	+32.4%